According to new MODULAR ATP data, the leadless system was associated with a high success rate and few complications. Boston Scientific plans on seeking FDA approval in 2025. 

Should patients stay on beta-blockers more than one year after a heart attack? The team behind the ABYSS clinical trial explored that very question, presenting its data at ESC Congress 2024.

ESC's annual meeting is always one of the world's largest gatherings of cardiologists and other cardiology professionals. This year's 4-day event will be no different. 

Researchers explored data from nearly 4,000 STEMI patients, noting that optical coherence tomography may be a valuable first step of any treatment strategy. 

"This breakthrough suggests that heart MRI could potentially replace invasive diagnostic tests," one specialist said. 

Finerenone, sold under the brand name Kerendia, is already approved by the FDA for reducing heart and kidney risks in patients with chronic kidney disease (CKD) and type 2 diabetes. Bayer plans on presenting the new data in full at ESC Congress 2024 in London. 

Inspired by nature and funded by the European Research Council, a group of scientists and engineers thinks its new research could represent a significant breakthrough in TAVR care.

HeartFlow's noninvasive Plaque Analysis technology, which uses AI to evaluate CCTA images, delivered assessments that mostly lined up with IVUS results.